Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents DOI Open Access
Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro

и другие.

Cancers, Год журнала: 2024, Номер 16(11), С. 1996 - 1996

Опубликована: Май 24, 2024

The treatment landscape for CLL has undergone a profound transformation with the advent of targeted agents (TAs) like Bruton's Tyrosine Kinase inhibitors (BTKis) and BCL-2 (BCL-2is). These target crucial cellular pathways in CLL, offering superior efficacy over traditional chemo-immunotherapy, which led to improved progression-free overall survival rates. This advancement promises enhanced disease control potentially normal life expectancy many patients. However, journey is not without challenges, as these TAs are associated range adverse events (AEs) that can impact patient quality life. review focuses on detailing various AEs related TA management evaluating their frequency clinical impact. aim present comprehensive guide effective AEs, ensuring optimal tolerability TAs. By reviewing existing literature consolidating findings, we provide insights into AE management, maximizing outcomes therapy.

Язык: Английский

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents DOI Open Access
Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro

и другие.

Cancers, Год журнала: 2024, Номер 16(11), С. 1996 - 1996

Опубликована: Май 24, 2024

The treatment landscape for CLL has undergone a profound transformation with the advent of targeted agents (TAs) like Bruton's Tyrosine Kinase inhibitors (BTKis) and BCL-2 (BCL-2is). These target crucial cellular pathways in CLL, offering superior efficacy over traditional chemo-immunotherapy, which led to improved progression-free overall survival rates. This advancement promises enhanced disease control potentially normal life expectancy many patients. However, journey is not without challenges, as these TAs are associated range adverse events (AEs) that can impact patient quality life. review focuses on detailing various AEs related TA management evaluating their frequency clinical impact. aim present comprehensive guide effective AEs, ensuring optimal tolerability TAs. By reviewing existing literature consolidating findings, we provide insights into AE management, maximizing outcomes therapy.

Язык: Английский

Процитировано

2